- nearly 80% of patients on IMDELLTRA-IMFINZI were alive at one year
- progression-free survival more than tripled
The Imdelltra-Imfinzi combination reduced the risk of death by 58% in first-line extensive-stage small cell lung cancer.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.